Is ketamine an appropriate rescue treatment for refractory cluster headache or migraine in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ketamine for Cluster Headache and Migraine

Do not use intravenous ketamine for acute migraine treatment in the emergency department or outpatient settings, as current guidelines recommend against it based on insufficient evidence of benefit. For cluster headache, ketamine may be considered only in highly refractory cases after failure of all standard therapies, though this remains off-label with limited evidence.

For Migraine

Guideline Recommendations

The most recent and authoritative guidelines explicitly advise against ketamine for migraine:

  • The 2024 VA/DoD guideline suggests against intravenous ketamine for short-term treatment of migraine (weak against recommendation) 1
  • The 2025 American Headache Society guideline for emergency department migraine treatment rates ketamine as "Level U - no recommendation" due to insufficient evidence 2
  • The 2025 American College of Physicians guideline makes no mention of ketamine in its treatment algorithm, instead recommending NSAIDs, acetaminophen, triptans, and their combinations 3

Why Ketamine Is Not Recommended for Migraine

The evidence base is inadequate. While some observational data exists, systematic reviews conclude the quality is very low with high risk of bias, small sample sizes, and heterogeneous outcomes 4. The FDA labeling for ketamine specifies it is approved only for anesthesia induction and maintenance, not headache treatment 5.

What to Use Instead

Follow this algorithmic approach for acute migraine:

  1. First-line: NSAID (ibuprofen 400-800mg, naproxen 500-1000mg) or acetaminophen 1000mg 3
  2. If inadequate response: Add a triptan (sumatriptan, rizatriptan, eletriptan, or zolmitriptan) to the NSAID or acetaminophen 3
  3. If combination fails: Consider CGRP antagonists (rimegepant, ubrogepant) or lasmiditan 3
  4. For ED presentation: Prochlorperazine IV or greater occipital nerve block (level A recommendations) 2

For Cluster Headache

Standard First-Line Treatments

For acute cluster attacks, use subcutaneous sumatriptan 6mg or intranasal zolmitriptan 10mg, along with high-flow oxygen (12-15 L/min via non-rebreather mask) 1. These have weak-for recommendations but represent the best available evidence.

Ketamine as Last Resort

Ketamine is not mentioned in any guideline for cluster headache treatment 1. However, limited research suggests potential benefit in highly refractory cases:

  • A 2020 case series showed that single ketamine-magnesium infusions (0.5 mg/kg over 2 hours) reduced daily attacks by 72% in refractory chronic cluster headache, with 76% achieving ≥50% reduction 6
  • A 2016 observational study reported complete attack abortion in 100% of episodic cluster patients and 54% of chronic cluster patients for 3-18 months 7
  • A 2022 open-label trial of intranasal ketamine showed 59% pain reduction at 30 minutes (though not at the 15-minute primary endpoint) 8

When to Consider Ketamine for Cluster Headache

Only consider ketamine if:

  • Patient has chronic cluster headache refractory to at least 3 preventive treatments
  • Failed acute treatments (oxygen, triptans)
  • Failed preventive treatments (verapamil, galcanezumab)
  • Treatment occurs in a monitored setting with appropriate safety protocols

Critical safety considerations: Ketamine requires continuous monitoring for hemodynamic instability, respiratory depression, and emergence reactions 5. It has abuse potential and should not be prescribed for home use without strict oversight 8. The FDA labeling emphasizes emergency airway equipment must be immediately available 5.

Important Caveats

Medication overuse headache risk: Using any acute treatment ≥10 days/month (triptans) or ≥15 days/month (NSAIDs) can cause rebound headaches 3. This threshold is unknown for ketamine but likely similar.

Cognitive effects: While one small study suggested no measurable cognitive impairment over 1 year in migraine patients receiving ketamine infusions 9, the sample size was inadequate for definitive conclusions, and some patients did experience worsening scores.

Long-term safety unknown: Chronic ketamine use has been associated with genitourinary pain and bladder dysfunction 5. The FDA label specifically warns about this in off-label chronic users.

Bottom line: Stick to guideline-recommended treatments. Ketamine for headache remains experimental, off-label, and should only be considered in tertiary headache centers for truly refractory cases after exhausting all standard options.

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.